Bristol Myers Squibb Drug Patent Portfolio

Bristol Myers Squibb's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Bristol Myers Squibb News

Is it a good time to invest in Bristol Myers Squibb after a 25% decline? - The Globe and Mail

21 Feb, 2026

Is it a good time to invest in Bristol Myers Squibb after a 25% decline? | The Motley Fool

21 Feb, 2026

Merck or Bristol Myers: Which Pharmaceutical Stock Will Be the Superior Choice in 2026? - Finviz

20 Feb, 2026

Will BMY's Growth Portfolio Offset the Decline of Legacy Medications by 2026? - Finviz

17 Feb, 2026

See More